Importantly, the PI3K/AKT pathway has been recognized to play key roles in anti-estrogen resistance of human breast cancer, with multiple inhibitors already developed and used in the clinics for patients who have failed earlier lines of endocrine therapy [64]. The gene discussed is AKT1; the disease is breast carcinoma.